Patents by Inventor Barbara Tomaino

Barbara Tomaino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isolated monophosphorylated peptide derived from human alpha-enolase useful for diagnosis and treatment of pancreatic adenocarcinoma, antibodies directed against the said monophosphorylated peptide, and uses thereof
    Patent number: 8895697
    Abstract: An isolated peptide of 12-20 amino acids in length comprising the amino acid sequence SEQ ID NO:1, wherein the serine residue (S) at position 8 of SEQ ID NO:1 is phosphorylated, is provided. Also provided is a human monophosphorylated alpha-enolase isoform wherein the serine residue (S) at position 419 of the human alpha-enolase amino acid sequence (SEQ ID NO:2) is phosphorylated and in which other post-translational modifications may be present. Further provided are antibodies capable of specifically binding the peptide and/or the isoform of the invention. The peptide, the isoform and the antibodies of the invention may be used in the diagnosis and/or amelioration and/or treatment of pancreatic adenocarcinoma.
    Type: Grant
    Filed: September 9, 2010
    Date of Patent: November 25, 2014
    Assignee: Natimab Therapeutics S.r.l.
    Inventors: Francesco Novelli, Barbara Tomaino, Paola Cappello
  • ISOLATED MONOPHOSPHORYLATED PEPTIDE DERIVED FROM HUMAN ALPHA-ENOLASE USEFUL FOR DIAGNOSIS AND TREATMENT OF PANCREATIC ADENOCARCINOMA, ANTIBODIES DIRECTED AGAINST THE SAID MONOPHOSPHORYLATED PEPTIDE, AND USES THEREOF
    Publication number: 20120164146
    Abstract: An isolated peptide of 12-20 amino acids in length comprising the amino acid sequence SEQ ID NO:1, wherein the serine residue (S) at position 8 of SEQ ID NO:1 is phosphorylated, is provided. Also provided is a human monophosphorylated alpha-enolase isoform wherein the serine residue (S) at position 419 of the human alpha-enolase amino acid sequence (SEQ ID NO:2) is phosphorylated and in which other post-translational modifications may be present. Further provided are antibodies capable of specifically binding the peptide and/or the isoform of the invention. The peptide, the isoform and the antibodies of the invention may be used in the diagnosis and/or amelioration and/or treatment of pancreatic adenocarcinoma.
    Type: Application
    Filed: September 9, 2010
    Publication date: June 28, 2012
    Applicants: NATIMAB THERAPEUTICS S.R.L.
    Inventors: Francesco Novelli, Barbara Tomaino, Paola Cappello
  • Antigens and antibodies associated to pancreatic ductal adenocarcinoma
    Patent number: 8071721
    Abstract: The present invention provides novel human protein antigens and related antibodies that have been identified as being specifically expressed in association to human Pancreatic Ductal Adenocarcinoma (PDA). In particular, novel phosphorylated isoforms of alpha-enolase have been identified in transformed cell lines of pancreatic origin and antibodies binding such isoforms are specifically present in the sera of PDA patients. These proteins and antibodies can be useful for the diagnosis and the treatment of PDA and other cancers having common molecular features.
    Type: Grant
    Filed: September 28, 2007
    Date of Patent: December 6, 2011
    Assignees: Ribovax Biotechnologies S.A., Bioline Diagnostici SRL
    Inventors: Francesco Novelli, Barbara Tomaino, Paola Cappello
  • Novel Antigens and Antibodies Associated to Pancreatic Ductal Adenocarcinoma
    Publication number: 20100028907
    Abstract: The present invention provides novel human protein antigens and related antibodies that have been identified as being specifically expressed in association to human Pancreatic Ductal Adenocarcinoma (PDA). In particular, novel phosphorylated isoforms of alpha-enolase have been identified in transformed cell lines of pancreatic origin and antibodies binding such isoforms are specifically present in the sera of PDA patients. These proteins and antibodies can be useful for the diagnosis and the treatment of PDA and other cancers having common molecular features.
    Type: Application
    Filed: September 28, 2007
    Publication date: February 4, 2010
    Applicants: Ribovax Biotechnologies SA, Bioline Diagnostici SRL
    Inventors: Francesco Novelli, Barbara Tomaino, Paola Cappello